Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection

Korean J Intern Med. 2015 Jul;30(4):550-3. doi: 10.3904/kjim.2015.30.4.550. Epub 2015 Jun 29.

Authors

Na-Ri Lee¹, Ji Won Jang², Hee Sun Kim³, Ho-Young Yhim¹

Affiliations

¹ Division of Hematology and Oncology, Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea. ; Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju, Korea.
² Division of Hematology and Oncology, Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea.
³ Department of Nursing, Wonkwang University School of Medicine, Iksan, Korea.

No abstract available

Keywords: Imatinib mesylate; Lung diseases, interstitial; Tuberculosis.

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Agents / adverse effects*
Antitubercular Agents / therapeutic use
Biopsy
Female
Gastrointestinal Stromal Tumors / drug therapy*
Gastrointestinal Stromal Tumors / pathology
Gastrointestinal Stromal Tumors / surgery
Humans
Imatinib Mesylate / adverse effects*
Lung Diseases, Interstitial / chemically induced*
Lung Diseases, Interstitial / diagnosis
Mycobacterium tuberculosis / isolation & purification*
Protein Kinase Inhibitors / adverse effects*
Rectal Neoplasms / drug therapy*
Rectal Neoplasms / pathology
Rectal Neoplasms / surgery
Tomography, X-Ray Computed
Tuberculosis, Pulmonary / diagnosis
Tuberculosis, Pulmonary / drug therapy
Tuberculosis, Pulmonary / microbiology*

Substances

Antineoplastic Agents
Antitubercular Agents
Protein Kinase Inhibitors
Imatinib Mesylate